en.Wedoany.com Reported - Boltz PBC, a US-based applied AI research lab, announced on June 18, 2026, a collaboration with Takeda to deploy its biomolecular AI models and platform within Takeda's research organization. Takeda's discovery teams will gain direct access to Boltz's latest proprietary biomolecular foundation models, including the recently released BoltzMol-1 and BoltzProt-1, for structure prediction and molecular design. Built on Boltz's open-source tools already used in the industry, the platform offers capabilities such as structure prediction, affinity estimation, and generative design for computer-aided molecular design.
Under the agreement, Takeda scientists will have access to the Boltz platform, including the Boltz Lab interface and the Boltz API, which enables programmatic access and integration into existing research workflows. The API supports integration with large language model agents, allowing researchers to orchestrate complex design and prediction workflows through natural language. Additionally, Boltz scientists will collaborate with Takeda on specific projects to fine-tune relevant models. Takeda will retain ownership of compounds generated using Boltz's models and platform.
Gabriele Corso, co-founder and CEO of Boltz, stated that the team is proud to deliver Boltz's state-of-the-art models to Takeda researchers and make AI a practical part of daily discovery work. He noted that from machine learning experts and computational scientists to medicinal chemists and protein engineers, Takeda teams can use these models through intuitive user interfaces, APIs, and agent integration. Hans Bitter, Head of Research Computational Science and Data Strategy at Takeda, said that Takeda is committed to combining cutting-edge science with the latest advances in artificial intelligence to accelerate drug discovery; by deploying Boltz's cutting-edge biomolecular models across the research organization, the hope is to provide scientists with practical tools to support structure prediction, molecular design, and more efficiently advance high-quality discovery projects.
Boltz PBC is a public-benefit AI research company with a core mission to empower every scientist to reinvent biology for a healthier, more sustainable future. The company's cutting-edge AI models have been adopted by leading pharmaceutical and biotechnology organizations for cross-modal biomolecular structure prediction, affinity estimation, and generative design.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
